会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 31. 发明申请
    • TAMPER RESISTANT DOSAGE FORM COMPRISING INORGANIC SALT
    • 含有无机盐的抗T药剂型
    • WO2012028319A1
    • 2012-03-08
    • PCT/EP2011/004406
    • 2011-09-01
    • GRÜNENTHAL GMBHBARNSCHEID, Lutz
    • BARNSCHEID, Lutz
    • A61K9/16A61K9/20A61K47/02
    • A61K47/02A61K9/2009A61K9/2031A61K31/135A61K31/485A61K47/10
    • The invention relates to a pharmaceutical dosage form exhibiting a breaking strength of at least 500 N, said dosage form containing a pharmacologically active ingredient (A); an inorganic salt (B); and a polyalkylene oxide (C) having a weight average molecular weight of at least 200,000 g/mol, wherein the content of the polyalkylene oxide (C) is at least 20 wt.-%, based on the total weight of the dosage form; wherein the pharmacologically active ingredient (A) is present in a controlled-release matrix comprising the inorganic salt (B) and the polyalkylene oxide (C) and wherein, under in vitro conditions, the release profile of the pharmacologically active ingredient (A) from said matrix comprises at least a time interval during which the release follows zero order kinetics.
    • 本发明涉及显示至少500N的断裂强度的药物剂型,所述剂型含有药理活性成分(A); 无机盐(B); 和重均分子量为至少200,000g / mol的聚环氧烷(C),其中聚环氧烷(C)的含量为至少20重量%,基于剂型的总重量; 其中药理活性成分(A)存在于包含无机盐(B)和聚环氧烷(C)的控释基质中,并且其中在体外条件下,药理活性成分(A)的释放曲线来自 所述矩阵包括至少一个时间间隔,在该时间间隔期间释放遵循零级动力学。
    • 35. 发明申请
    • EMULSIONS FOR REMOVAL AND PREVENTION OF DEPOSITS
    • 去除和防止沉积物的乳液
    • WO2012022451A1
    • 2012-02-23
    • PCT/EP2011/004067
    • 2011-08-12
    • ASHLAND LICENSING AND INTELLECTUAL PROPERTY LLC.BIERGANNS, PatricBROECHER, MarkusKANTO-OEQUIST, Charlotta
    • BIERGANNS, PatricBROECHER, MarkusKANTO-OEQUIST, Charlotta
    • D21H21/04D21C9/08C11D7/50
    • C11D17/0017C11D1/662C11D1/72C11D1/74C11D1/825C11D3/18C11D3/43D21C9/08
    • The invention relates to an aqueous cleansing emulsion comprising (a) a hydrophobic component Hi selected from the group consisting of the following categories: (i) aliphatic C 10 - or C 15 -terpene hydrocarbons; (ii) aliphatic C 10 - or C 15 -terpenoids; (iii) aliphatic C 15 -C 40 -hydrocarbons; and (iv) C 6 -C 30 -carboxylic acid C 1 -C 30 -alkyl esters; (b) a hydrophobic component H2 selected from the group consisting of the following categories: (iii) aliphatic C 20 -C 40 -hydrocarbons; (iv) C 6 -C 30 -carboxylic acid Ci-C3o-alkyl esters; (v) aliphatic C 6 -C 19 -hydrocarbons; (vi) aromatic C 10 - or C 15 -terpenoids; (vii) aliphatic or aromatic C 20 -. C 25 -, C 30 - or C 35 -terpenoids; (viii) essential, animal or vegetable oils; and (ix) silicon oils; with the proviso that H 1 and H 2 are neither both selected from category (iii) nor both selected from category (iv); (c) an emulsifier having a HLB value of 4±2; (d) an emulsifier E 2 having a HLB value of 9±2; and (e) optionally, an emulsifier E 3 having an HLB value of 16±4.
    • 本发明涉及含水清洁乳液,其包含(a)选自以下类别的疏水组分Hi:(i)脂族C 10 - 或C 15 - 萜烯烃; (ii)脂族C 10 - 或C 15 - 萜类化合物; (iii)脂族C 15 -C 40烃; 和(iv)C 6 -C 30羧酸C 1 -C 30烷基酯; (b)选自以下类别的疏水组分H 2:(iii)脂族C 20 -C 40烃; (iv)C 6 -C 30羧酸C 1 -C 30烷基酯; (v)脂族C 6 -C 19烃; (vi)芳香族C10-或C15-萜类化合物; (vii)脂族或芳族C20-。 C25-,C30-或C35-萜类化合物; (viii)必需,动物或植物油; 和(ix)硅油; 条件是H1和H2既不选自第(iii)类,也不选自第(iv)类; (c)HLB值为4±2的乳化剂; (d)HLB值为9±2的乳化剂E2; 和(e)任选地,HLB值为16±4的乳化剂E3。
    • 36. 发明申请
    • HOT-MELT EXTRUDED CONTROLLED RELEASE DOSAGE FORM
    • HOT-MELT EXTREDED CONTROLLED RELEASE剂型
    • WO2011009602A1
    • 2011-01-27
    • PCT/EP2010/004459
    • 2010-07-21
    • GRÜNENTHAL GMBHBARNSCHEID, LutzGALIA, Eric
    • BARNSCHEID, LutzGALIA, Eric
    • A61K9/20A61K31/137
    • A61K9/2072A61K9/2031A61K9/2054A61K9/2095A61K31/137
    • The invention relates to a hot-melt extruded pharmaceutical dosage form with controlled release of a pharmacologically active ingredient (A) embedded in a matrix comprising a polymer (C), the dosage form exhibiting a breaking strength of at least 300 N and having an oblong shape comprising a longitudinal direction of extension, a transversal direction of extension orthogonal to the longitudinal direction of extension, a front side, an opposite back side and a circumferential rim between said front and back side; wherein the core of the pharmaceutical dosage form has a morphological orientation caused by hot-melt extrusion that is substantially orthogonal to the longitudinal direction of extension of the dosage form; and/or - the release per area of the pharmacologically active ingredient (A) through the front side and the opposite back side is faster than the release through the circumferential rim.
    • 本发明涉及一种具有控制释放包含聚合物(C)的基质中的药理学活性成分(A)的热熔挤出药物剂型,所述剂型具有至少300N的断裂强度并且具有长方形 形状,其包括纵向延伸方向,垂直于所述纵向延伸方向的横向方向,所述前侧和后侧之间的前侧,相对的后侧和周向边缘; 其中所述药物剂型的核心具有由与所述剂型的延伸长度方向基本正交的热熔融挤出引起的形态取向; 和/或 - 通过前侧和相对的后侧的药理学活性成分(A)的每个面积的释放比通过周缘的释放快。
    • 38. 发明申请
    • VERFAHREN ZUR ERZEUGUNG EINER VARIANTEN-BIBLIOTHEK VON DNA-SEQUENZEN
    • 过程用于产生DNA序列的变体文库
    • WO2009146892A1
    • 2009-12-10
    • PCT/EP2009/003945
    • 2009-06-03
    • C-LECTA GMBHGREINER-STÖFFELE, ThomasFELLER, ClaudiaSTRUHALLA, Marc
    • GREINER-STÖFFELE, ThomasFELLER, ClaudiaSTRUHALLA, Marc
    • C12N15/10C12Q1/68
    • C12N15/1093C12N15/102
    • Die Erfindung betrifft ein Verfahren zur Erzeugung einer Varianten-Bibliothek von DNA- Sequenzen ausgehend von mindestens einer DNA-Ausgangssequenz umfassend die folgenden Schritte: a) Auswählen von mindestens zwei Mutationsstellen in der DNA-Ausgangssequenz; b) Unterteilen der DNA-Ausgangssequenz in mindestens zwei Sequenzabschnitte in einer Weise, so dass mindestens zwei dieser Sequenzabschnitte jeweils mindestens eine der Mutationsstellen umfassen; c) Amplifizieren der Sequenzabschnitte durch PCR mit Hilfe von insgesamt wenigstens fünf verschiedenen Oligonukleotiden, wobei (i) sich an jede der Mutationsstellen mindestens eines der Oligonukleotide anlagern kann; (ii) sich an mindestens eine Mutationsstelle wenigstens zwei der Oligonukleotide anlagern können; und (iii) in den durch PCR erhaltenen Amplifikations-Produkten durch die Oligonukleotide an den Mutationsstellen über Mismatch -Positionen Mutationen eingeführt werden, wobei an mindestens einer der Mutationsstellen mindestens zwei Mutationen eingeführt werden; und d) Verknüpfen der Amplifikations-Produkte zu DNA-Sequenzen.
    • 本发明涉及一种方法,用于从至少一个DNA序列输出包括以下步骤产生DNA序列的变体文库:a)选择在该DNA序列输出突变的至少两个位点; b)将所述DNA序列输出,使得至少两种这些序列区段的每个包括以这样的方式突变位点中的至少一个的至少两个序列段; c)中通过PCR扩增的序列段具有总共至少五个不同的寡核苷酸,其中(i的帮助下)可以附加到每个所述寡核苷酸中的至少一个的突变位点的; (二)能够附着到至少一个突变位点中的至少两个寡核苷酸; 和(iii)被引入到在突变位点不匹配通过定位突变,通过PCR扩增产物所获得由寡核苷酸的结果,至少两个突变的突变位点中的至少一个引入的; 以及d)连接的扩增产物的DNA序列。